GoodRx Holdings (GDRX) Receivables - Net (2019 - 2026)

GoodRx Holdings' Receivables - Net history runs 8 years deep, the most recent figure standing at $232.7 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 45.34% year-over-year to $232.7 million; the TTM figure through Mar 2026 stood at $232.7 million (up 45.34% YoY), while the FY2025 annual figure was $235.7 million, up 61.54% from the prior year.
• Receivables - Net came in at $232.7 million for Q1 2026 at GoodRx Holdings, down from $235.7 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $235.7 million in Q4 2025 to a low of $116.4 million in Q1 2023.
• A 5-year average of $152.6 million and a median of $143.6 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net surged 65.7% in 2022 and dropped 5.55% in 2023, its largest moves.
• GoodRx Holdings' Receivables - Net stood at $117.1 million in 2022, then advanced by 22.59% to $143.6 million in 2023, then grew by 1.62% to $145.9 million in 2024, then surged by 61.54% to $235.7 million in 2025, then fell by 1.28% to $232.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $232.7 million, $235.7 million, and $203.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison